Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.9517 +0.0304 (+3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Dyadic International Narrows Q2 Loss
Via The Motley Fool
Dyadic (DYAI) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Dyadic Revenue Jumps 150% in Fiscal Q2
Via The Motley Fool
Topics Intellectual Property
Dyadic International Inc (NASDAQ:DYAI) Reports Mixed Q2 2025 Earnings Amid Strategic Rebranding
Dyadic International (DYAI) reported mixed Q2 2025 results, beating revenue estimates but posting an EPS loss. Shares dipped as investors weigh its rebranding and shift to commercial operations. 
Via Chartmill
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Earnings Scheduled For August 13, 2025
 
Via Benzinga
A Look at Dyadic International's Upcoming Earnings Report
 
Via Benzinga
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Wednesday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
From Dyadic Applied BioSolutions
Via Business Wire
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
From Dyadic International, Inc.
Via GlobeNewswire
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at World Vaccine Congress | Washington
From Dyadic International, Inc.
Via GlobeNewswire
Power Nickel (TSX.V: PNPN) – Undervalued Precious, Battery, Energy and Base Metals Play Amidst Gold Surge – More Stocks Inside
Via AB Newswire
Earnings Scheduled For March 26, 2025
 
Via Benzinga
Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors
Via AB Newswire
Topics Artificial Intelligence
Dyadic (NASDAQ: DYAI) Secures $3M Gates Foundation Grant to Advance Global Vaccines & Therapeutics with C1 Fungal Platform – More Stocks Inside
Via AB Newswire
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Attend Multiple Industry Events in March
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics 
From Dyadic International, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.